Results 151 to 160 of about 343,793 (239)

When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ‐PET Centiloid 15, Mean Age of 66 Years

open access: yesAnnals of Neurology, EarlyView.
Objective Sporadic late‐onset Alzheimer's disease (AD) is characterized by a long pre‐clinical phase where amyloid‐beta (Aβ) and tau begin to accumulate in the brain. The primary objective was to determine the age at which AD starts by finding the average population age when both positron emission tomography (PET) Aβ (Aβ‐PET) and plasma Aβ42/40 become ...
Rodrigo Cánovas   +29 more
wiley   +1 more source

Diagnostic potential of circular RNAs in carotid atherosclerotic plaque vulnerability. [PDF]

open access: yesNoncoding RNA Res
Greco S   +13 more
europepmc   +1 more source

Tau Pathology in Alzheimer's Disease Uniquely Affects Sulcal Depths

open access: yesAnnals of Neurology, EarlyView.
Objective Though it is widely known that tau deposition affects brain structure, the precise localization of these effects is poorly understood, especially in relation to gyral and sulcal anatomy. We investigated whether tau pathology in Alzheimer's disease (AD) preferentially affects sulci, and particularly sulcal depths.
Samira A. Maboudian   +10 more
wiley   +1 more source

Artificial intelligence-powered automatic coronary computed tomography angiography plaque quantification: comparison against optical coherence tomography. [PDF]

open access: yesEur Heart J Digit Health
Li G   +15 more
europepmc   +1 more source

Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers

open access: yesAnnals of Neurology, EarlyView.
Objective This study aimed to compare positron emission tomography (PET) and plasma‐based temporal modeling of amyloid and tau biomarkers in Alzheimer's disease. Methods Longitudinal amyloid PET (n = 1,097, mean age ± SD = 72.5 ± 7.38 year, 51.4% male), 18F‐flortaucipir tau‐PET (n = 230, 74.3 ± 7.18 year, 52.2% female), and Fujirebio Lumipulse plasma p‐
Christopher A. Brown   +14 more
wiley   +1 more source

Serum metabolomics coupled with HR-VWI radiomics reveals metabolic alterations in asymptomatic carotid artery stenosis. [PDF]

open access: yesJ Cereb Blood Flow Metab
Fan Y   +9 more
europepmc   +1 more source

Novel Monoclonal Antibody Detects Small Aβ Oligomers More Sensitively Than Lecanemab in Alzheimer's Disease CSF, Serum and Culture Media

open access: yesAnnals of Neurology, EarlyView.
Objective Aqueously diffusible oligomers of the amyloid β‐protein (oAβ) are neurotoxic and play a role in neuronal dysfunction in Alzheimer's disease (AD). Accurate quantification of oAβ in brains and biofluids could be valuable for understanding and monitoring AD.
Yi Ran Xu   +11 more
wiley   +1 more source

Simultaneous Imaging of Cu+ and Cu2+ in Neural Cells Using DNAzyme Probes Reveals Mechanistic Link Between Copper Redox Imbalance and Amyloid Pathology

open access: yesAngewandte Chemie, EarlyView.
We develop Cu+‐ and Cu2+‐specific DNAzyme fluorescent probes to visualize both copper redox states in living neurons. Aβ oligomers cause intracellular copper overload, triggering FDX1 dependent cuproptosis and generating ROS. This work links copper redox imbalance with Aβ pathology and offers a selective, sensitive way to monitor copper homeostasis in ...
Xiangli Shao   +6 more
wiley   +2 more sources

Association between Plasma P‐tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's Disease

open access: yesAnnals of Neurology, EarlyView.
Objective Clinically relevant Alzheimer's disease co‐pathology is common in Lewy body disorders. Plasma P‐tau217 is a sensitive biomarker for amyloid and tau pathology in Alzheimer's disease. The objective was to determine if plasma P‐tau217 associates with Alzheimer's disease co‐pathology and cognition in Lewy body disorders. Methods Participants had (
Thomas F. Tropea   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy